Results of PIA analysis and primary outcome
| Phosphorylated FLT3 . | No. of patients . | No. (%) with CR/CRp . |
|---|---|---|
| Patients with samples available for analysis | 79 | 21 (26.6) |
| Inhibited at aplasia assessment | 46 | 18 (39.1) |
| Not inhibited at aplasia assessment | 33 | 3 (9.1) |
| Inhibited both at aplasia and outcome assessments | 21 | 12 (57.1) |
| Phosphorylated FLT3 . | No. of patients . | No. (%) with CR/CRp . |
|---|---|---|
| Patients with samples available for analysis | 79 | 21 (26.6) |
| Inhibited at aplasia assessment | 46 | 18 (39.1) |
| Not inhibited at aplasia assessment | 33 | 3 (9.1) |
| Inhibited both at aplasia and outcome assessments | 21 | 12 (57.1) |
The difference in the CR/CRp rate between those who were inhibited at the aplasia assessment and those who were not was highly significant (P = .004; Fisher exact test).